Search Results - "Bianco, A.R."

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment by Duffy, S., Jackson, T.L., Lansdown, M., Philips, K., Wells, M., Pollard, S., Clack, G., Coibion, M., Bianco, A.R.

“…BACKGROUND: Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1–2 years of treatment and a quadrupling after 5 years…”
Get full text

First-line systemic therapy for metastatic breast cancer and management of pleural effusion by Perrone, F, Carlomagno, C, De Placido, S, Lauria, R, Morabito, A, Bianco, A R

Get more information

The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data by Duffy, S, Jackson, T.L, Lansdown, M, Philips, K, Wells, M, Pollard, S, Clack, G, Cuzick, J, Coibion, M, Bianco, A.R

“…The ATAC ( Arimidex, Tamoxifen, Alone or in Combination) trial is a randomised, double-blind trial comparing ‘Arimidex’ (anastrozole), alone or in combination…”
Get full text

Targeting c-erbB2 and Other Receptors of the C-ErbB Family: Rationale and Clinical Applications by Bianco, A.R.

“…The c-erbB family of receptors includes four distinct receptors, namely c-erb B1, 2, 3 and 4 (HER1, 2, 3 and 4, respectively). Trastuzumab (T) is a recombinant…”
Get full text

The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data by Duffy, S., Jackson, T.L., Lansdown, M., Philips, K., Wells, M., Pollard, S., Clack, G., Cuzick, J., Coibion, M., Bianco, A.R.

“…Objective The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial is a randomised, double‐blind trial comparing ‘Arimidex’ (anastrozole), alone or in…”
Get full text

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy by Duffy, S., Jackson, T.L., Lansdown, M., Philips, K., Wells, M., Pollard, S., Clack, G., Coibion, M., Bianco, A.R.

“…BACKGROUND: The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial is a randomized, double-blind trial comparing anastrozole (‘Arimidex’), alone or in…”
Get full text

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study by Gridelli, C., Perrone, F., Gallo, C., De Marinis, F., Ianniello, G., Cigolari, S., Cariello, S., Di Costanzo, F., D'Aprile, M., Rossi, A., Migliorino, R., Bartolucci, R., Bianco, A.R., Pergola, M., Monfardini, S.

“…More than 30% of lung cancers arise in patients aged 70 years or more; however, because elderly patients are not considered to tolerate chemotherapy, they are…”
Get full text

Recombinant IFN-α2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells by Quesada, P, Malanga, M, Di Meglio, S, De Lorenzo, S, Fabbrocini, A, Garbi, C, Bianco, A.R, Pepe, S

“…In the present paper, we investigated the relationship between the growth inhibitory effects of recombinant interferon-α2b (rIFN-α2b) and poly (ADPR)…”
Get full text

Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer by Tortora, G., Ciardiello, F., Damiano, V., De Laurentiis, M., Matano, E., Pepe, S., Pensabene, M., Catalano, G., De Placido, S., Bianco, A. R.

“…Background DNA damage caused by platinum agents is frequently followed by induction of topoisomerase I, providing a rationale for use of platinum-based…”
Get full text

Poly(ADP-ribose)polymerase (PARP-1) expression in malignant melanomas from photo exposed areas of the head and neck region by Staibano, S., Pepe, S., Lo Muzio, L., Somma, P., Argenziano, G., Soyer, P., Fabbrocini, G., Gaetano, S., Mezza, E., Molea, G., Laus, G., Bianco, A.R., De Rosa, G.

Get full text

Epidermal growth factor receptor (EGFR) expression in cutaneous melanoma: A possible role as prognostic marker by Staibano, S., Pepe, S., Soyer, P., Argenziano, G., Somma, P., Mansueto, G., Mascolo, M., Bianco, A.R., Laus, G., De Rosa, G.

Get full text

A structured algorithm to assess the response to biological therapy in medullary thyroid carcinoma by Vitale, G., Tagliaferri, P., Caraglia, M., Rampone, E., Ciccarelli, A., Abbruzzese, A., Bianco, A.R., Lupoli, G.

Get full text

Oral administration of chimeric MBO antisense-protein kinase A inhibits growth, angiogenesis and growth factors production and cooperates with cytotoxic drugs in human cancer xenografts by Tortora, G., Damiano, V., Bianco, R., Fontanini, G., Caputo, R., De Placido, S., Bianco, A.R., Agrawal, S., Ciardiello, F.

Get full text

Antiangiogenic and antitumor effect of VEGF antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in human colon cancer by Ciardiello, F., Bianco, R., Damiano, V., Caputo, R., De Placido, S., Fontanini, G., Agrawal, S., Mendelsohn, J., Bianco, A.R., Tortora, G.

Get full text

1086 Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC) by Van Cutsem, E., Gascón Vilaplana, P., Seitz, J.F., Van Laethem, J.L., Grossi, F., Bianco, A.R., Dueland, S., Bets, D., Mueser, M.

Get full text

Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial by Gridelli, C., Perron, F., Palmeri, S., D'Aprile, M., Cognetti, F., Rossi, A., Gebbia, V., Pepe, R., Veltri, E., Airoma, G., Russo, A., Incoronato, P., Scinto, A. F., Palazzolo, G., Natali, M., Leonardi, V., Gallo, C., De Placido, S., Bianco, A. R.

“…Purpose: To compare mitomycin C plus vindesine plus etoposide (MEV) vs. mitomycin C plus vindesine plus cisplatin (MVP) in the treatment of stage IV…”
Get full text

5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells by Caraglia, M, Pinto, A, Correale, P, Zagonel, V, Genua, G, Leardi, A, Pepe, S, Bianco, A R, Tagliaferri, P

“…The epidermal growth factor (EGF-R) receptor is an important growth regulator of epithelial cancer cells, and is presently considered a tumor-associated…”
Get more information

Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study by De Placido, S, Lauria, R, Perrone, F, Vernaglia Lombardi, A, Carlomagno, C, Varriale, E, Costanzo, R, Leo, L, De Laurentiis, M, Bianco, A R

“…Second-line treatment of patients with metastatic breast cancer resistant to anthracyclines is an important clinical issue. The aim of the present two-stage…”
Get more information

P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy by Bianco, A.R., De Laurentiis, M., Carlomagno, C., Lauria, R., Petrella, G., Panico, L., Pettinato, G., Perrone, F., Gallo, C., Marinelli, A., De Placido, S.

Get full text

Postmastectomy follow-up in patients with early breast cancer: consensus or controversy? by Bianco, A R, Perrone, F

Get more information